BrightSpring Forecasts $760M–$790M EBITDA With 18%–23% Core Growth, Mitigates IRA Impact to ~$15M
BrightSpring forecasts 2026 EBITDA of $760M–$790M, reflecting core growth of 18%–23% excluding Amedisys LLC assets and anticipates 16–18 limited distribution drug launches. Company mitigated IRA headwinds to ~$15M via PBM fee negotiations and plans to reduce leverage to around 2.5x by year-end 2026.
1. 2026 Guidance and Growth Drivers
BrightSpring forecasts 2026 EBITDA of $760M–$790M, excluding acquired assets from Amedisys LLC implies 18%–23% core growth. The company expects broad-based volume growth across specialty, infusion and home pharmacy and plans margin expansion through ongoing operational efficiencies and favorable service and drug mix dynamics.
2. IRA Impact Mitigation
BrightSpring reduced its 2026 Inflation Reduction Act headwind from an estimated $35M–$40M to about $15M by negotiating enhanced dispensing fees with PBMs and leveraging CMS guidance. It expects the IRA’s impact to decline to roughly 50% of 2026’s level in 2027, assuming no further changes to mitigation measures.
3. Limited Distribution Drug Launches
The company plans to launch approximately 16–18 limited distribution drugs in 2026, while prior-year launch cohorts from 2023 to 2025 continue to ramp and support EBITDA margin leverage. A new home infusion operational team with dedicated sales and business development leadership aims to expand access across acute and chronic markets.
4. Balance Sheet and Integration Strategy
Leverage improved from a 4.5x post-IPO peak to a pro forma 2.6x after the Community Living divestiture, targeting about 2.5x or below by the end of 2026. BrightSpring intends to use divestiture proceeds to pay down debt, pursue selective tuck-in acquisitions, and execute a deliberate integration of Amedisys health assets to drive future growth.